Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-γ enzyme-linked immunosorbent spots

Transplantation

Volumn 86, Issue 4, 2008, Pages 529-534

  Augustine, Joshua J ^a   Poggio, Emilio D ^b   Heeger, Peter S ^c   Hricik, Donald E ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute rejection; Alloimmunity; Immune monitoring; Kidney transplantation; T cell

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; FINGOLIMOD; GAMMA INTERFERON; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADJUVANT THERAPY; ADULT; ALLOIMMUNITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME; AGED; ANTIBODY PRODUCTION; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GRAFT REJECTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; RETROSPECTIVE STUDY; STATISTICS; T LYMPHOCYTE;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; INTERFERON TYPE II; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TISSUE DONORS;

EID: 52449122317     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31818046db     Document Type: Article

References (19)

1. Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in anti-thymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460.
2. Mourad G, Garrigue V, Squifflet, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001; 72: 1050.
3. Szczech LA, Berline JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998; 128: 817.
4. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161.
5. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350: 1193.
6. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999; 67: 276.
7. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769.
8. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48.
9. Brennan DC, Daller JA, Lake KD, et al. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
10. Crompton JA, Somerville T, Smith L, et al. Lack of economic benefit with basiliximab induction in living related donor adult renal transplant recipients. Pharmacotherapy 2003; 23: 443.
11. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 2267.
12. Augustine JJ, Siu DS, Clemente MJ, et al. Pre-transplant IFN-gamma ELIS-POTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5: 1971.
13. Gebauer BS, Hricik DE, Atallah A, et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002; 2: 857.
14. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
15. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465.
16. Bonnefoy-Berard N, Verrier B, Vincent C, et al. Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins. Immunology 1992; 77: 61.
17. Jones DL, Sacks SH, Wong W. Controlling the generation and function of human CD8+ memory T cells in vitro with immunosuppressants. Transplantation 2006; 82: 1352.
18. van Besouw NM, Balk AHMM, van Vliet M, et al. Anti-CD25 therapy impairs donor-specific Th1 and Th2 cytokine-producing peripheral blood cells after clinical heart transplantation. Transplant Proc 2002; 34: 2942.
19. Blachere NE, Morris HK, Braun D, et al. IL-2 is required for the activation of memory CD8+ T cells via antigen cross-presentation. J Immunol 2006; 176: 7288.